|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
US5156965A
(en)
|
1983-11-29 |
1992-10-20 |
Igen, Inc. |
Catalytic antibodies
|
|
US5229272A
(en)
|
1989-04-25 |
1993-07-20 |
Igen, Inc. |
Catalytic antibody components
|
|
US5126258A
(en)
|
1984-09-07 |
1992-06-30 |
Scripps Clinic And Research Foundation |
Molecules with antibody combining sites that exhibit catalytic properties
|
|
US5030717A
(en)
|
1986-09-17 |
1991-07-09 |
Scripps Clinic And Research Foundation |
Antibodies which catalyze hydrolysis of ester bonds
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
US5851527A
(en)
|
1988-04-18 |
1998-12-22 |
Immunomedics, Inc. |
Method for antibody targeting of therapeutic agents
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5858728A
(en)
|
1991-03-13 |
1999-01-12 |
Common Services Agency |
Monoclonal antibody against LPS core
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
EP0696318A4
(en)
|
1993-04-23 |
1998-04-15 |
Igen Inc |
CATALYTIC ANTIBODIES HYDROLYZING PRIMARY AMIDES AND METHOD FOR DISPLAYING THESE ANTIBODIES
|
|
US5602021A
(en)
|
1994-12-29 |
1997-02-11 |
Catalytic Antibodies, Inc. |
Method for generating proteolytic enzymes specific against a selected peptide sequence
|
|
US5585108A
(en)
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US6667044B1
(en)
|
1996-10-04 |
2003-12-23 |
Beiersdorf Ag |
Cosmetic or dermatological gels based on microemulsions
|
|
WO1998016254A1
(en)
|
1996-10-17 |
1998-04-23 |
Immunomedics, Inc. |
Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
WO1998056425A1
(en)
|
1997-06-11 |
1998-12-17 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
|
|
IT1293511B1
(it)
|
1997-07-30 |
1999-03-01 |
Gentili Ist Spa |
Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
|
|
US6703488B1
(en)
|
1998-01-15 |
2004-03-09 |
Center For Molecular Medicine And Immunology |
Antibody/receptor targeting moiety for enhanced delivery of armed ligand
|
|
ES2322975T3
(es)
|
1998-01-15 |
2009-07-02 |
Center For Molecular Medicine And Immunology |
Componente direccionador biespecifico que comprende un anticuerpo contra el antigeno carcinoembrionario (cea) y la region de union a ligando de la subunidad alfa del receptor de il-13.
|
|
US6855804B2
(en)
|
1998-03-23 |
2005-02-15 |
Board Of Regents, The University Of Texas System |
Covalently reactive transition state analogs and methods of use thereof
|
|
US6235714B1
(en)
|
1998-03-23 |
2001-05-22 |
Sudhir Paul |
Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
|
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
|
US7223556B1
(en)
|
1998-10-09 |
2007-05-29 |
President And Fellows Of Harvard College |
Targeted proteolysis by recruitment to ubiquitin protein ligases
|
|
DE60036388D1
(de)
|
1999-07-30 |
2007-10-25 |
Medarex Inc |
Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen
|
|
EP1231944A2
(en)
|
1999-11-15 |
2002-08-21 |
University Of Southern California |
Targeted delivery of therapeutic and diagnostic moieties
|
|
DE10034607A1
(de)
|
2000-07-20 |
2002-02-07 |
Gundram Jung |
Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
|
|
US7041298B2
(en)
|
2000-09-08 |
2006-05-09 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20070258987A1
(en)
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
|
US7431923B2
(en)
|
2005-01-03 |
2008-10-07 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7534429B2
(en)
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
CA2462883A1
(en)
|
2001-10-12 |
2003-04-17 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
|
BR0215238A
(pt)
|
2001-12-21 |
2005-05-31 |
Alcon Inc |
Uso de nanopartìculas inor ânicas sintéticas como veìculos para drogas oftálmicas e óticas
|
|
US7332585B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20050142141A1
(en)
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
JP2006527590A
(ja)
|
2003-06-18 |
2006-12-07 |
ディレボ・ビオテク・アーゲー |
新規生物学的実体およびその使用
|
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
|
MXPA06004853A
(es)
|
2003-11-07 |
2006-07-06 |
Immunex Corp |
Anticuerpos que se aglutinan al receptor 4 de interleucina.
|
|
US7371539B2
(en)
|
2003-12-03 |
2008-05-13 |
President And Fellows Of Harvard College |
Targeted polypeptide degradation
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
US8754031B2
(en)
*
|
2004-03-08 |
2014-06-17 |
Oncolix, Inc. |
Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
|
|
AR048098A1
(es)
|
2004-03-15 |
2006-03-29 |
Wyeth Corp |
Conjugados de caliqueamicina
|
|
EP1877099B1
(en)
|
2005-04-06 |
2012-09-19 |
Genzyme Corporation |
Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
|
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
CN101374546B
(zh)
*
|
2005-12-16 |
2016-03-23 |
Ibc医药公司 |
基于免疫球蛋白的多价生物活性装配体
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
ES2398076T3
(es)
|
2006-06-02 |
2013-03-13 |
Regeneron Pharmaceuticals, Inc. |
Anticuerpos de alta afinidad contra el receptor de IL-6 humano
|
|
US20080089891A1
(en)
|
2006-07-26 |
2008-04-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
|
US9127293B2
(en)
*
|
2006-07-26 |
2015-09-08 |
The University Of Chicago |
Receptor-mediated delivery: compositions and methods
|
|
EP2054444B1
(en)
|
2006-08-04 |
2016-11-02 |
MedImmune Limited |
Antibodies to erbb2
|
|
AR062435A1
(es)
*
|
2006-08-18 |
2008-11-05 |
Xoma Technology Ltd |
Anticuerpo especifico prlr (receptor de prolactina) y sus usos
|
|
WO2008122039A2
(en)
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
|
JP2010528285A
(ja)
|
2007-05-23 |
2010-08-19 |
ベンタナ・メデイカル・システムズ・インコーポレーテツド |
免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
|
|
US20090258005A1
(en)
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
WO2008151219A1
(en)
|
2007-06-04 |
2008-12-11 |
Regeneron Pharmaceuticals, Inc. |
Enhanced expression and stability regions
|
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
|
EP2238162A1
(en)
|
2008-01-24 |
2010-10-13 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Induced internalization of surface receptors
|
|
WO2009120922A2
(en)
|
2008-03-27 |
2009-10-01 |
Zymogenetics, Inc. |
Compositions and methods for inhibiting pdgfrbeta and vegf-a
|
|
EP4154903A1
(en)
|
2008-04-22 |
2023-03-29 |
Vib Vzw |
Liver-specific nucleic acid regulatory elements and methods and use thereof
|
|
EP2276506A4
(en)
|
2008-04-30 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
|
EP2374481B1
(en)
|
2008-07-21 |
2015-11-04 |
Polytherics Limited |
Novel reagents and method for conjugating biological molecules
|
|
AU2009296297A1
(en)
|
2008-09-26 |
2010-04-01 |
Roche Glycart Ag |
Bispecific anti-EGFR/anti-IGF-1R antibodies
|
|
MX2011010166A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
|
EP2241576A1
(en)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
|
|
JP5816170B2
(ja)
|
2009-06-26 |
2015-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
|
JP5954789B2
(ja)
|
2009-08-10 |
2016-07-20 |
ユーシーエル ビジネス パブリック リミテッド カンパニー |
機能的分子の可逆的共有結合
|
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
|
SI2501817T2
(sl)
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
DK2528625T3
(da)
|
2010-04-15 |
2013-10-14 |
Spirogen Sarl |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
WO2011140279A1
(en)
|
2010-05-04 |
2011-11-10 |
Wayne State University |
Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
|
|
CN114805583A
(zh)
|
2010-05-27 |
2022-07-29 |
根马布股份公司 |
针对her2的单克隆抗体
|
|
US20130244905A1
(en)
|
2010-07-06 |
2013-09-19 |
Ed Grabczyk |
Reporter for RNA Polymerase II Termination
|
|
WO2012136519A1
(en)
|
2011-04-06 |
2012-10-11 |
Bayer Pharma Aktiengesellschaft |
Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
|
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対する二重特異性抗体
|
|
US20120282176A1
(en)
|
2011-04-20 |
2012-11-08 |
Roche Glycart Ag |
Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier
|
|
CA2832389A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
KR20140037105A
(ko)
|
2011-05-27 |
2014-03-26 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
|
|
EP2530089A1
(en)
|
2011-06-03 |
2012-12-05 |
Bayer Pharma Aktiengesellschaft |
Neutralising prolactin receptor antibody Mat3 and its therapeutical use
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
ES2945932T3
(es)
|
2011-10-14 |
2023-07-10 |
Seagen Inc |
Pirrolobenzodiazepinas y conjugados dirigidos
|
|
CA2850103C
(en)
|
2011-10-14 |
2019-09-10 |
Spirogen Sarl |
Pyrrolobenzodiazepines
|
|
CA2850096C
(en)
|
2011-10-14 |
2018-07-03 |
Spirogen Sarl |
Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
|
|
WO2013055993A1
(en)
|
2011-10-14 |
2013-04-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
CN104244718A
(zh)
|
2011-12-05 |
2014-12-24 |
伊格尼卡生物治疗公司 |
抗体-药物缀合物以及相关化合物、组合物和方法
|
|
MX361875B
(es)
|
2012-03-14 |
2018-12-18 |
Regeneron Pharma |
Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
|
|
US20150125449A1
(en)
|
2012-05-10 |
2015-05-07 |
Zymeworks Inc. |
Single-Arm Monovalent Antibody Constructs and Uses Thereof
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
FI2911699T4
(fi)
|
2012-10-23 |
2025-12-09 |
Synaffix Bv |
Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
|
|
HUE039334T2
(hu)
|
2012-11-27 |
2018-12-28 |
Biomarin Pharm Inc |
Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai
|
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
EP2981551B1
(en)
|
2013-02-20 |
2020-06-03 |
Valerion Therapeutics, LLC |
Methods and compositions for treatment of pompe disease
|
|
EP2968538A1
(en)
|
2013-03-15 |
2016-01-20 |
Bayer HealthCare LLC |
Anti-prolactin receptor antibody formulations
|
|
MX379256B
(es)
|
2013-03-15 |
2025-03-10 |
Regeneron Pharma |
Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
WO2014189973A2
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
CN104211814A
(zh)
|
2013-05-29 |
2014-12-17 |
三星电子株式会社 |
用于消耗靶膜蛋白的组合物
|
|
TWI641620B
(zh)
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
US9545451B2
(en)
|
2013-08-21 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
|
|
KR102252925B1
(ko)
|
2013-08-26 |
2021-05-18 |
리제너론 파마슈티칼스 인코포레이티드 |
마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
|
|
ES2919749T3
(es)
|
2014-06-11 |
2022-07-28 |
Molecular Templates Inc |
Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
MA41022A
(fr)
|
2014-11-24 |
2017-10-03 |
Shire Human Genetic Therapies |
Ciblage lysosomial et utilisations correspondantes
|
|
EA034950B1
(ru)
|
2015-03-27 |
2020-04-09 |
Регенерон Фармасьютикалз, Инк. |
Производные майтанзиноида, их конъюгаты и способы использования
|
|
MY189159A
(en)
|
2015-07-06 |
2022-01-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
AU2016365834B2
(en)
|
2015-12-08 |
2023-09-28 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
WO2017132173A1
(en)
|
2016-01-25 |
2017-08-03 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
|
CN109071658A
(zh)
|
2016-02-05 |
2018-12-21 |
根马布股份公司 |
具有改进的内化特性的多特异性抗原-结合分子
|
|
EP4275751A3
(en)
|
2016-02-24 |
2023-12-27 |
BioMarin Pharmaceutical Inc. |
Improved naglu fusion protein formulation
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
FI3635009T3
(fi)
|
2017-06-07 |
2026-04-07 |
Regeneron Pharma |
Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
|
|
JP7779653B2
(ja)
|
2018-02-07 |
2025-12-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
治療用タンパク質送達のための方法および組成物
|